Pricing Log in Create free account
Saturday 17 October 2026 Export PAVM’s income statement to Excel — free account

PAVmed Inc.

PAVM Healthcare Medical Devices

PAVmed Inc.’s revenue for fiscal 2025 (year ended December 2025) was $71,000.00, down 97.6% from fiscal 2024. In the quarter to June 2026, revenue grew 450.0%, EPS grew 96.1% and free cash flow fell 125.6%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

2.41 0.02 −0.82%
Market cap
$19.4M
P/E
0.0×
Fwd P/E
−1.7×
Dividend yield
—
F-score
2/9
Altman Z
−11.40
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 33.81%

Capital & Financial Ratios $m

Market Cap 19.39
Revenue 0.11
Net Income (16.43)
Free Cash Flow (7.78)
Net Debt 11.32
Current Ratio 1.19
Debt/Equity 0.78
P/E ratio 0.00
Fwd P/E (1.74) (negative: loss-making)
P/S ratio 134.90 (above 10: high)
P/B ratio 0.98
Past 5Y EPS Growth —
This Y EPS Growth 35.70% (at or above 15%: strong)
Next Y EPS Growth 45.30% (at or above 15%: strong)
Next Y revenue growth 227.46% (at or above 10%: strong)
Next 5Y EPS Growth 59.25% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 236×, against a ten-year median of 5.4×; over the ten years it ranged from −15.3× in 2022 to 434× in 2026.
P/S against its own 10 years 83.25%
10-year low 10-year high
P/B against its own 10 years 11.62%
10-year low 10-year high
EV/Sales against its own 10 years 79.53%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 20 1 2 4
Receivables 0 0 0 0
Inventory 0 — — —
Other — — — —
24 2 3 5
2023 2024 2025 Q'26
Payables 2 1 1 1
ST’ Debt — — — —
Other — — — —
54 35 15 4

Compound Annual Growth %

10y 5y 3y
Sales — — (42.68%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 42.77% 0.00% 26.82%

Revenue $m

Mar Jun Sep Dec Year
’26 0 0 — — —
’25 0 0 0 0 0
’24 1 1 1 0 3
’23 0 0 1 1 2
’22 0 — 0 0 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) (3) — — —
’25 (2) (1) (1) (2) (5)
’24 (13) (12) (9) 0 (34)
’23 (16) (13) (11) (12) (52)
’22 (12) (23) (19) (17) (71)
’21 (9) (7) (8) (17) (41)
’20 (4) (6) (6) (7) (22)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) (3) — — —
’25 (2) (1) (1) (2) (5)
’24 (13) (12) (9) 0 (33)
’23 (15) (13) (11) (12) (51)
’22 (13) (23) (20) (17) (73)
’21 (9) (7) (8) (18) (42)
’20 (4) (6) (6) (7) (22)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (4.42) (0.87) — — —
’25 10.21 (22.22) (8.71) (2.05) (5.63)
’24 (78.68) (35.74) 43.24 3.60 13.08
’23 (85.54) (63.03) (72.04) (59.46) (275.07)
’22 (90.04) (130.56) (130.56) (103.55) (450.22)
’21 (58.53) (63.03) (67.53) (90.04) (292.65)
’20 (148.57) (58.53) (49.52) (76.54) (328.66)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 2,250.00 855.00 391.50 364.50 513.00 882.00 180.45 82.50 17.16 6.30

Analyst estimates 2026–2028

Powerpack
High 9,572.83 4,189.50 1,791.00 618.75 1,552.50 4,365.00 1,165.50 296.10 128.70 26.85
People
People Employees 3 5 9 15 25 89 124 107 39 41
Revenue/emp, $m 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.02 0.08 0.00
Income, $m
Income, $m Revenue — — — — — 1 0 2 3 0
Gross margin, % 0.00 0.00 0.00 0.00 0.00 (17.00) (858.62) (161.83) (61.60) (207.04)
EBT (6) (10) (18) (17) (36) (56) (103) (79) 28 (2)
EBT margin, % 0.00 0.00 0.00 0.00 0.00 (11,225.20) (27,384.08) (3,232.59) 949.15 (3,477.46)
Net income (6) (10) (18) (17) (36) (56) (103) (79) 28 (2)
Depreciation 0 0 2 0 0 0 2 3 1 0
Per share, $
Per share, $ Revenue 0.00 0.00 0.00 0.00 0.00 2.90 1.91 10.18 9.29 0.11
Earnings (198.10) (346.67) (378.19) (247.62) (328.66) (292.65) (450.22) (275.07) 88.17 (5.63)
Cash flow (154.68) (220.27) (177.53) (199.06) (207.91) (235.72) (359.05) (216.10) (104.08) (7.76)
Capex (0.76) (0.18) (0.54) (0.40) (0.52) (8.53) (7.79) 3.15 0.92 (0.05)
Free cash flow (155.44) (220.45) (178.07) (199.46) (208.43) (244.25) (366.84) (212.95) (103.16) (7.81)
Book value (11.08) (94.95) (50.02) (69.12) (4.49) 461.20 55.31 (99.74) (21.81) 33.26
Shares, m 0 0 0 0 0 0 0 0 0 1
Valuation, ×
Valuation, × P/E — — — — — 0.00 0.00 0.00 0.23 0.91
P/S — — — — — 0.00 64.39 11.96 2.03 62.61
P/B — — — — — 2.48 5.29 0.00 0.00 0.00
EV/Sales — — — — — 0.00 8.41 5.32 2.75 88.03
EV/FCF — — — — — (3.02) (0.08) (0.25) (0.25) (1.28)
Cash, $m
Cash, $m Operating cash flow (4) (7) (9) (13) (22) (41) (71) (52) (34) (5)
Capex 0 0 0 0 0 (1) (2) 1 0 0
Free cash flow (4) (7) (9) (13) (22) (42) (73) (51) (33) (5)
Balance, $m
Balance, $m Working capital 0 (1) (3) (5) (1) 75 3 (30) (33) (12)
Total debt — 2 8 8 14 — 2 — — —
Net debt (1) 0 (8) (6) (17) (77) (40) (20) (1) (2)
Shareholders’ equity 0 (3) (2) (5) 0 79 11 (24) (7) 22
Returns, %
Returns, % ROA (542.18) (828.50) (369.98) (212.59) (255.85) (94.85) (126.66) (152.17) 100.24 (10.86)
ROIC 0.00 0.00 0.00 0.00 0.00 (1,573.87) 0.00 0.00 0.00 (65.64)
ROE (3,590.15) 495.14 447.03 292.38 695.15 (136.86) (209.45) 706.05 (171.12) 59.31
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

PAVmed Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
PMI Flag Ship Acquisition Corp $23.4M 0.5× — (loss-making) +38.62% (above 0%: growing) n/m +46.79% (above 0%: growing) 20.85% (156.70%) Compare
NSPR InspireMD, Inc. $22.3M — (loss-making) — (loss-making) −0.39% (below 0%: shrinking) n/m −26.00% (below 0%: shrinking) (43.70%) (815.64%) Compare
ARAY Accuray Incorporated $20.8M — (loss-making) — (loss-making) −20.87% (below 0%: shrinking) n/m +117.83% (above 0%: growing) 35.22% 5.47% Compare
MODD Modular Medical, Inc. $20.5M — (loss-making) — — n/m −5.61% (below 0%: shrinking) 0.00% 0.00% Compare
PAVM PAVmed Inc. $19.4M — (loss-making) — (loss-making) +450.00% (above 0%: growing) n/m −125.63% (below 0%: shrinking) (269.70%) (21,278.79%)
BDMD Baird Medical Investment Holdings Limited $19.2M — (loss-making) — — n/m −598.12% (below 0%: shrinking) — — Compare
LFWD Lifeward Ltd. $17.2M — (loss-making) — (loss-making) +15.71% (above 0%: growing) n/m −52.77% (below 0%: shrinking) 40.90% (62.69%) Compare
ALUR Allurion Technologies, Inc. $16.7M — (loss-making) — (loss-making) −47.19% (below 0%: shrinking) n/m +65.98% (above 0%: growing) 41.70% (126.60%) Compare
HSCS HeartSciences Inc. $15.4M — (loss-making) — (loss-making) −46.15% (below 0%: shrinking) n/m +18.18% (above 0%: growing) 61.90% (139,957.14%) Compare
Median of peers $19.9M — — −10.63% — +6.28% 35.22% (126.60%)

All 149 Medical Devices stocks →

PAVmed Inc. (PAVM) key facts

  • Concern: PAVmed Inc.’s revenue for fiscal 2025 (year ended December 2025) was $71,000.00, down 97.6% from fiscal 2024.
  • PAVmed Inc. (PAVM) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, PAVM traded at $2.41, a market capitalization of $19.4 million.
  • Return on equity was 59.3% and debt-to-equity 0.78.
  • Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −11.40 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

PAVmed Inc. (PAVM) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/PAVM · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com